Inhibiting Proliferation and Metastasis of Cancer Cells

Technology #32194

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Full length (LIMK), constitutively active phosphomimic (LIMKCA), LIMdomain only (LIMKLD), and kinase-domain only (LIMKKD) LIMK1 constructs were cloned into the pCMV14 vector used for expression in RWPE1 cells
Ratna Chakrabarti, Ph.D.
Patent Protection

Methods and compositions for inhibiting the proliferation of cancer cells

US Patent 8,802,649 B2

Methods and compositions for inhibiting the proliferation of cancer cells

US Patent 8,415,315 B2

Co-targeting of aurora A kinase and LIM kinase 1 for cancer therapy

US Patent 8,911,725 B2

This discovery provides methods and compounds for decreasing the expression of LIMK1 and AurKA in cancer cells.

Metastasis of tumor cells contributes to about 90% of cancer-related deaths. Proteins that regulate cell motility are attractive targets for cancer therapy because they can also play key roles in cell survival, proliferation, and migration. Lim kinase 1 (LIMK1) is a protein that is involved in cell motility and is frequently overexpressed in highly aggressive and metastatic cancer cells. The current discovery encompasses compounds for the inhibition of LIMK1 expression. Inhibiting LIMK1 with UCF’s proprietary compounds reduces the growth, proliferation, and invasiveness of prostate cancer cells. Additionally, these compounds can be used with Aurora A kinase (AurKA) inhibitors in combinatorial cancer therapy. This combination allows for the effective use of each inhibitor at lower dosages, minimizing the toxicities commonly associated with cancer treatments.


  • Ease of synthesis
  • Combined use of LIMK1 inhibitors and AurKA inhibitors reduces toxicity


  • The current discovery can be used for the development of:
    • Drugs for treating or preventing the proliferation and metastasis of cancer cells
    • Markers for cancer detection

Additional Technology Numbers:  32698